Unique ID issued by UMIN | UMIN000004789 |
---|---|
Receipt number | R000005695 |
Scientific Title | Feasibility Study of Adjuvant Chemotherapy with UFT Following Stereotactic Body Radiation Therapy for Clinical Stage I Non-Small Cell Lung Cancer (LOGIK-1001) |
Date of disclosure of the study information | 2010/12/24 |
Last modified on | 2021/02/15 14:25:41 |
Feasibility Study of Adjuvant Chemotherapy with UFT Following Stereotactic Body Radiation Therapy for Clinical Stage I Non-Small Cell Lung Cancer (LOGIK-1001)
Feasibility Study of UFT following Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer. (LOGIK-1001)
Feasibility Study of Adjuvant Chemotherapy with UFT Following Stereotactic Body Radiation Therapy for Clinical Stage I Non-Small Cell Lung Cancer (LOGIK-1001)
Feasibility Study of UFT following Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer. (LOGIK-1001)
Japan |
Clinical Stage I Non-small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy
Pneumology | Radiology |
Malignancy
NO
To evaluate the safety of adjuvant UFT following stereotactic body radiation therapy
Safety
Pragmatic
Phase II
Completion Rate of UFT therapy
Adverse events, Grade 2 or greater radiation pneumonitis, Disease-free survival, Overall survival
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
UFT250 mg/m2(daily oral administration)for 2years
20 | years-old | <= |
Not applicable |
Male and Female
1.Histologically or transbronchoscopic cytologically or Clinically(exe. FDG-PET) confirmed non-small cell lung cancer
2.StageIB(T1-2a, N0, M0) with images
3.Undergone curative stereotactic body radiation therapy
4.No prior therapy other than stereotactic body radiation therapy
5.Aged 20<= years.
6.ECOG performance status of 0-1.
7.Required baseline laboratory parameters (within 2 weeks before registration):
WBC >= 3000/mm3
Neu >= 1,500/ mm3
Hb >= 10g/dl
Plt >= 100,000/ mm3
GOT < 100IU/ml
GPT < 100IU/ml
T-Bil <= 2.0mg/dl
Cre <= 1.5mg/dl
PaO2 >= 60Torr
8.Written informed consent.
1.Apparent interstitial pneumonitis and fibrosis
2.Active inflammation without oral drugs
3.Double cancer
4.Pregnancy
5.Psychiatric disorder
6.Steroid administration
7.Oxygen administration
8.Fever of 38.0 degrees centigrade or higher
45
1st name | |
Middle name | |
Last name | Yukito Ichinose |
National Hospital, Kyushu Cancer Center
Department of Thoracic Oncology
3-1-1 Notame, Minami-ku, Fukuoka, 811-1395
092-541-3231
yichinos@nk-cc.go.jp
1st name | |
Middle name | |
Last name | Yoshiyuki Shioyama |
Kyushu University, Graduate School of Medical Sciences
Department of Heavy Particle Therapy and Radiation Oncology
3-1-1 Maidashi, higashi-ku, Fukuoka, Japan , 812-8582
092-642-5695
shioyama@radiol.med.kyushu-u.ac.jp
Lung Oncology Group in Kyushu, Japan (LOGIK)
Clinical Research Support Center Kyushu
Non profit foundation
Japan
NO
九州大学病院(福岡県)
浜の町病院(福岡県)
福岡大学病院(福岡県)
国立病院機構 福岡東医療センター(福岡県)
済生会福岡総合病院(福岡県)
飯塚病院(福岡県)
国立病院機構 大牟田病院(福岡県)
北九州市立医療センター(福岡県)
新別府病院(大分県)
大分県立病院(大分県)
九州大学病院別府先進医療センター(大分県)
長崎大学病院(長崎県)
熊本大学病院(熊本県)
沖縄県立南部医療センター・こども医療センター(沖縄県)
2010 | Year | 12 | Month | 24 | Day |
Unpublished
Completed
2010 | Year | 03 | Month | 24 | Day |
2011 | Year | 01 | Month | 14 | Day |
2010 | Year | 05 | Month | 01 | Day |
2014 | Year | 04 | Month | 01 | Day |
2010 | Year | 12 | Month | 24 | Day |
2021 | Year | 02 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005695